Sulistio A, Mansfeld F, Reyes-Ortega F, et al. Intra-articular Treatment of Osteoarthritis with Diclofenac-Conjugated Polymer Reduces Inflammation and Pain. CS Appl. Bio Mater (2019), 2, 2822−2832. doi: 10.1021/acsabm.9b00232.
Sulistio A, Reyes-Ortega F, D’Souza AM, et al. Precise control of drug loading and release of an NSAID-polymer conjugate for long term osteoarthritis intra-articular drug delivery. J Mater Chem B. 2017 Aug 21;5(31):6221-6226. doi: 10.1039/c7tb01518f. Epub 2017 Jul 31. PMID: 32264436.

Wang F, Finnin J, Tait C, et al. The Hydrolysis of Diclofenac Esters: Synthetic Prodrug Building Blocks for Biodegradable Drug-Polymer Conjugates. J Pharm Sci. 2016 Feb;105(2):773-785. doi: 10.1002/jps.24665. Epub 2016 Jan 29. PMID: 26540508.

Hart E, Azzopardi K, Taing H, et al. Efficacy of antimicrobial polymer coatings in an animal model of bacterial infection associated with foreign body implants. J Antimicrob Chemother. 2010 May;65(5):974-80. doi: 10.1093/jac/dkq057. Epub 2010 Mar 16. PMID: 20233779.


PolyActiva is developing products based on its proprietary Prezia technology and through a series of patent filings has a comprehensive intellectual property portfolio to protect them throughout the major jurisdictions.

PolyActiva’s portfolio currently has 8 active patent families comprising over 120 granted patents and a further 34 applications pending (as of 30 September 2023).

PolyActiva’s glaucoma program is specifically protected by 4 patent families with 31 granted patents and a further 33 pending applications.

Additional filings are ongoing.